PR Newswire BiotechOriginal article
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Regulatoryapprovediza-brenPositive
AI Analysis
Summary
SystImmune announced its parent company Sichuan Biokin Pharmaceutical received NMPA approval for iza-bren as the second indication in China for treating recurrent or metastatic esophageal squamous cell carcinoma.
Outcome Details
Second approval in China from NMPA for iza-bren
Importance:6/10
Sentiment:
0.70
China approvalNMPAesophageal cancerregulatory approval
Related Companies
Read the original article
Published by PR Newswire Biotech on July 17, 2026 12:00 PM